OF
OFIX.US Orthofix Medical Inc
- Market cap
- USD 292M
- P/E
- -
- P/B
- 0.68x
- ROE
- -13.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OFIX.US undervalued?
Graham numberThe Graham number of Orthofix Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orthofix Medical Inc fundamental analysis
No fundamental analysis for Orthofix Medical Inc yet.
Orthofix Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orthofix Medical Inc
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation impl…
Full company profileOrthofix Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orthofix Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 410M | 434M | 453M | 460M | 407M | 464M | 461M | 747M | 799M | 822M | 821M |
| Gross Profit | 322M | 341M | 356M | 359M | 305M | 350M | 337M | 486M | 546M | 552M | 581M |
| Operating Income | 21.1M | 40.8M | 30.1M | -18.8M | -6.27M | -8.32M | -13.3M | -139M | -84.6M | -68.5M | -25.2M |
| EBITDA | 39.9M | 60.9M | 41.5M | 1.55M | 36.4M | 21.4M | 15.7M | -79.5M | -18.3M | 9.93M | 5.10M |
| Net Income | 3.06M | 6.22M | 13.8M | -28.5M | 2.52M | -38.4M | -19.7M | -151M | -126M | -92.2M | -57.0M |
| EPS | 0.17 | 0.34 | 0.73 | -1.51 | 0.13 | -1.95 | -0.98 | -4.12 | -3.30 | -2.31 | -1.39 |
| Balance Sheet | |||||||||||
| Total Assets | 372M | 405M | 467M | 496M | 526M | 477M | 459M | 925M | 893M | 851M | 856M |
| Total Liabilities | 109M | 109M | 131M | 168M | 169M | 140M | 122M | 327M | 390M | 401M | 426M |
| Shareholders' Equity | 263M | 297M | 335M | 328M | 357M | 337M | 337M | 599M | 503M | 450M | 430M |
| Cash & Short-term Investments | 39.6M | 81.2M | 69.6M | 69.7M | 96.3M | 87.8M | 50.7M | 33.1M | 83.2M | 82.0M | 86.3M |
| Total Debt | - | - | - | 22.8M | 24.9M | 24.3M | 21.5M | 117M | 180M | 229M | 235M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 44.7M | 53.3M | 49.9M | 32.0M | 74.3M | 18.5M | -11.5M | -45.8M | 25.8M | 33.3M | -31.3M |
| Capital Expenditure | 18.3M | 16.9M | 15.3M | 20.5M | 17.1M | 19.6M | 23.2M | 62.1M | 34.9M | 34.6M | 50.4M |
| Free Cash Flow | 26.4M | 36.4M | 34.7M | 11.5M | 57.2M | -1.12M | -34.7M | -108M | -9.09M | -1.28M | -81.7M |
| Ratios | |||||||||||
| ROE | 1.2% | 2.1% | 4.1% | -8.7% | 0.7% | -11.4% | -5.9% | -25.3% | -25.0% | -20.5% | -13.3% |
| ROA | 0.8% | 1.5% | 3.0% | -5.7% | 0.5% | -8.1% | -4.3% | -16.4% | -14.1% | -10.8% | -6.7% |
| Net Profit Margin | 0.7% | 1.4% | 3.0% | -6.2% | 0.6% | -8.3% | -4.3% | -20.3% | -15.8% | -11.2% | -7.0% |
| Debt to Equity | - | - | - | 0.07x | 0.07x | 0.07x | 0.06x | 0.20x | 0.36x | 0.51x | 0.55x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orthofix Medical Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.73M | 0.09 | - |
| 2021 | USD 2.56M | 0.13 | - |
| 2020 | USD 2.49M | 0.13 | 99.0% |
| 2019 | USD 5.19M | 0.27 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Orthofix Medical Inc
- Insiders 2.69%
- Institutions 97.31%
- Public & others 0.00%
- Shares outstanding 40.8M
- Free float 40.4M
Top funds holding OFIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.21M | 2.98% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.01M | 2.47% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 441K | 1.08% | 0.00% | Aug 2026 |
| Paradigm Micro-Cap | 400K | 0.98% | 0.00% | Oct 2026 |
| iShares Russell 2000 Value ETF | 363K | 0.89% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 235K | 0.58% | +1.05% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 212K | 0.52% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 194K | 0.48% | +19.27% | Sep 2026 |
| iShares US Medical Devices ETF | 193K | 0.47% | -1.12% | Oct 2026 |
| 1290 VT GAMCO Small Company Value IB | 185K | 0.45% | 0.00% | Sep 2026 |
| Lazard Baylight US Sm Cap Eq WW Dist EUR | 166K | 0.41% | +0.60% | Jul 2026 |
| Fidelity Enhanced Small Cap Core ETF | 166K | 0.41% | +0.27% | Oct 2026 |
| Fidelity VIP Disciplined Small Cap Init | 153K | 0.37% | 0.00% | Aug 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 150K | 0.37% | +43.45% | Jul 2026 |
| DFA US Micro Cap I | 129K | 0.32% | +7.57% | Sep 2026 |
| iShares Micro-Cap ETF | 122K | 0.30% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap I | 117K | 0.29% | 0.00% | Sep 2026 |
| Paradigm Select | 100K | 0.25% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 97.9K | 0.24% | +0.11% | Sep 2026 |
| Dimensional US Small Cap ETF | 97.1K | 0.24% | 0.00% | Oct 2026 |
Top institutions holding OFIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Engine Capital Management LP | 4.58M | 11.23% | +4.21% | Jun 2026 |
| Juniper Investment Co, LLC | 4.44M | 10.90% | +11.71% | Jun 2026 |
| Rubric Capital Management LP | 3.72M | 9.13% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.33M | 8.16% | +3.70% | Jun 2026 |
| Paradigm Capital Management, Inc. | 3.30M | 8.10% | -0.13% | Jun 2026 |
| Armistice Capital, LLC | 3.26M | 8.01% | +20.89% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.73M | 4.25% | +4.57% | Jun 2026 |
| Geode Capital Management, LLC | 1.05M | 2.57% | +11.63% | Jun 2026 |
| State Street Corp | 953K | 2.34% | +5.04% | Jun 2026 |
| AQR Capital Management LLC | 887K | 2.18% | +369.15% | Jun 2026 |
| Millennium Management LLC | 862K | 2.12% | -19.20% | Jun 2026 |
| Acadian Asset Management LLC | 843K | 2.07% | -5.03% | Sep 2026 |
| Dimensional Fund Advisors, Inc. | 672K | 1.65% | -8.17% | Sep 2026 |
| Jacobs Levy Equity Management, Inc. | 481K | 1.18% | +26.83% | Jun 2026 |
| The Goldman Sachs Group Inc | 446K | 1.09% | +37.52% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 405K | 0.99% | +2.09% | Jun 2026 |
| Northern Trust Corp | 364K | 0.89% | +7.87% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 344K | 0.84% | +71.90% | Jun 2026 |
| Charles Schwab Investment Management Inc | 335K | 0.82% | +2.72% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 296K | 0.73% | +49.82% | Jun 2026 |
Orthofix Medical Inc company profile
- Company name
- Orthofix Medical Inc
- Ticker
- OFIX.US
- Exchange
- USA Stocks
- Listed since
- Apr 24, 1992
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,605
- Fiscal year end
- December
- Address
- 3451 Plano Parkway, Lewisville, TX, United States, 75056
- Phone
- 214 937 2000
- Website
- orthofix.com
About Orthofix Medical Inc
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Orthofix Medical Inc management
10- Mr. Massimo CalafiorePresident, CEO & Director · born 1972
- Ms. Julie B. AndrewsChief Financial Officer · born 1971
- Ms. Aviva McPherronPresident of Global Operations & Quality · born 1977
- Mr. J. Andres CedronChief Legal Officer & Corporate Secretary · born 1981
- Mr. Patrick FisherPresident of Global Biologics & Limb Reconstruction · born 1974
- Mr. Geoffrey C. GillespieChief Accounting Officer
- Ms. Julie D. DeweyChief Investor Relations & Communications Officer · born 1961
- Ms. Jill MasonChief Compliance & Risk Officer
- Ms. Stephanie WalshChief Human Resources Officer
- Dr. Beau Standish P.Eng., Ph.D.Chief Enabling Technologies Officer · born 1980